CL2017003436A1 - Compuestos de benzoxacepina oxazolidinona y métodos de uso - Google Patents

Compuestos de benzoxacepina oxazolidinona y métodos de uso

Info

Publication number
CL2017003436A1
CL2017003436A1 CL2017003436A CL2017003436A CL2017003436A1 CL 2017003436 A1 CL2017003436 A1 CL 2017003436A1 CL 2017003436 A CL2017003436 A CL 2017003436A CL 2017003436 A CL2017003436 A CL 2017003436A CL 2017003436 A1 CL2017003436 A1 CL 2017003436A1
Authority
CL
Chile
Prior art keywords
methods
pi3k
benzoxacepin
oxazolidinone compounds
compounds
Prior art date
Application number
CL2017003436A
Other languages
English (en)
Inventor
Marie-Gabrielle Braun
Richard Elliott
Emily Hanan
Robert Andrew Heald
Calum Macleod
Steven T Staben
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2017003436A1 publication Critical patent/CL2017003436A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B43/00—Formation or introduction of functional groups containing nitrogen
    • C07B43/06—Formation or introduction of functional groups containing nitrogen of amide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>EN EL PRESENTE DOCUMENTO SE DESCRIBEN COMPUESTOS DE BENZOXACEOINA OXAZOLIDINONA CON ACTIVIDAD O FUNCIÓN MODULADORA DE FOSFOINOSITIDO 3 CINASA (PI3K) QUE TIENEN LA ESTRUCTURA DE FÓRMULA 1, O ESTEREOISÓMEROS, TAUTÓMEROS, O SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS, Y CON LOS SUSTITUYENTES Y CARACTERÍSTICAS ESTRUCTURALES DESCRITAS EN EL PRESENTE DOCUMENTO. TAMBIÉN SE DESCRIBEN COMPOSICIONES FARMACÉUTICAS Y MEDICAMENTOS QUE INCLUYEN LOS COMPUESTOS DE FÓRMULA 1, ASÍ COMO MÉTODOS PARA USAR DICHOS MODULADORES DE PI3K, SOLOS O EN COMBINACIÓN CON OTROS AGENTES TERAPÉUTICOS, PARA TRATAR ENFERMEDADES O AFECCIONES QUE ESTÁN MEDIADAS O QUE SON DEPENDIENTES DE LA DESREGULACIÓN DE PI3K.</p>
CL2017003436A 2015-07-02 2017-12-28 Compuestos de benzoxacepina oxazolidinona y métodos de uso CL2017003436A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562188029P 2015-07-02 2015-07-02

Publications (1)

Publication Number Publication Date
CL2017003436A1 true CL2017003436A1 (es) 2018-05-04

Family

ID=56292756

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017003436A CL2017003436A1 (es) 2015-07-02 2017-12-28 Compuestos de benzoxacepina oxazolidinona y métodos de uso

Country Status (34)

Country Link
US (6) US9650393B2 (es)
EP (4) EP3567045B1 (es)
JP (4) JP6523490B2 (es)
KR (2) KR102014326B1 (es)
CN (4) CN112047960B (es)
AR (1) AR105238A1 (es)
AU (2) AU2016287463B2 (es)
CA (1) CA2982708C (es)
CL (1) CL2017003436A1 (es)
CO (1) CO2017011038A2 (es)
CR (1) CR20170563A (es)
DK (1) DK3317284T3 (es)
ES (2) ES2764497T3 (es)
HK (1) HK1253003A1 (es)
HR (1) HRP20192349T1 (es)
HU (1) HUE046756T2 (es)
IL (3) IL255200B (es)
LT (1) LT3317284T (es)
MA (3) MA49861A (es)
MX (2) MX2020003415A (es)
MY (1) MY195002A (es)
NZ (2) NZ736222A (es)
PE (2) PE20181021A1 (es)
PH (2) PH12017502425A1 (es)
PL (2) PL3567045T3 (es)
PT (1) PT3317284T (es)
RS (1) RS59740B1 (es)
RU (1) RU2730529C2 (es)
SG (1) SG10201913980SA (es)
SI (1) SI3317284T1 (es)
TW (4) TWI698440B (es)
UA (1) UA121678C2 (es)
WO (1) WO2017001645A1 (es)
ZA (1) ZA201808370B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3094197C (en) 2015-07-02 2023-02-28 F. Hoffmann-La Roche Ag Bicyclic lactams and methods of use thereof
WO2017001658A1 (en) 2015-07-02 2017-01-05 F. Hoffmann-La Roche Ag Benzoxazepin oxazolidinone compounds and methods of use
UA121678C2 (uk) * 2015-07-02 2020-07-10 Ф. Хоффманн-Ля Рош Аг Сполука бензоксазепіноксазолідинонів та способи застосування
JP6873977B2 (ja) 2015-09-08 2021-05-19 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 三環式ｐｉ３ｋ阻害化合物及び使用方法
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
WO2018073193A1 (en) 2016-10-17 2018-04-26 F. Hoffmann-La Roche Ag Bicyclic pyridone lactams and methods of use thereof
EP3851441B1 (en) * 2016-12-15 2023-06-28 F. Hoffmann-La Roche AG Process for the preparation of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino) propanamide
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
WO2018197653A1 (en) * 2017-04-28 2018-11-01 F. Hoffmann-La Roche Ag Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production
JP7398391B2 (ja) 2018-04-20 2023-12-14 エフ． ホフマン－ラ ロシュ アーゲー Ｎ－［４－オキソ－２，３－ジヒドロ－１，５－ベンズオキサゼピン－３－イル］－５，６－ジヒドロ－４Ｈ－ピロロ［１，２－ｂ］ピラゾール－２－カルボキサミド誘導体及び例えば過敏性腸症候群（ＩＢＳ）を処置するためのＲＩＰ１キナーゼ阻害剤としての関連化合物
JP7456945B2 (ja) * 2018-05-30 2024-03-27 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 三環式誘導体を含む阻害剤、その製造方法、及び使用
WO2020023297A1 (en) * 2018-07-23 2020-01-30 Genentech, Inc. Methods of treating cancer with pi3k inhibitor, gdc-0077
TW202027736A (zh) 2018-10-08 2020-08-01 瑞士商赫孚孟拉羅股份公司 用PI3Kα抑制劑及二甲雙胍治療癌症之方法
CN109265408B (zh) * 2018-12-11 2020-09-01 上海皓元生物医药科技有限公司 二氟甲基取代噁烷-2-酮的合成方法
CN113195000A (zh) 2018-12-21 2021-07-30 第一三共株式会社 抗体-药物缀合物和激酶抑制剂的组合
CN111995541A (zh) * 2019-05-27 2020-11-27 润佳（苏州）医药科技有限公司 含有稳定重同位素的酰胺官能团的化合物及其应用
CN114599656A (zh) * 2019-11-04 2022-06-07 贝达药业股份有限公司 咪唑烷酮类化合物及其制备方法与应用
CN112830935B (zh) * 2019-11-25 2023-12-22 上海翰森生物医药科技有限公司 含三并环类衍生物自由碱的晶型及其药物组合物
AU2020389670A1 (en) * 2019-11-25 2022-05-19 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Three fused ring derivative-containing salt or crystal form and pharmaceutical composition thereof
IL293347A (en) * 2019-12-03 2022-07-01 Genentech Inc Combined therapies for the treatment of breast cancer
EP4259662A1 (en) 2020-12-11 2023-10-18 Genentech, Inc. Combination therapies for treatment of her2 cancer
JP2024504811A (ja) * 2021-01-29 2024-02-01 メッドシャイン ディスカバリー インコーポレイテッド 三環式化合物及びその使用
MX2023013305A (es) 2021-05-13 2024-01-31 Betta Pharmaceuticals Co Ltd Compuesto polimorfo de imidazolidinona, método de preparación del mismo y uso del mismo.
IL308457A (en) 2021-05-28 2024-01-01 Genentech Inc A process for preparing benzoxazepine oxazolidinone compounds
EP4358550A4 (en) 2021-07-19 2024-10-16 Kyocera Corp COMMUNICATION PROCESS
US20230321102A1 (en) 2022-04-06 2023-10-12 Genentech, Inc. TREATMENT OF CANCER USING COMBINATION THERAPIES COMPRISING GDC-6036 and GDC-0077
WO2024022435A1 (zh) * 2022-07-27 2024-02-01 南京明德新药研发有限公司 一种5,6-二氢苯并[f]咪唑并[1,2-d][1,4]噁吖庚英化合物的晶型及其制备方法
WO2024100236A1 (en) 2022-11-11 2024-05-16 Astrazeneca Ab Combination therapies for the treatment of cancer
WO2024206147A1 (en) 2023-03-24 2024-10-03 Arvinas Operations, Inc. Dosage regimens of estrogen receptor degraders

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5846824A (en) 1994-02-07 1998-12-08 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
US6274327B1 (en) 1992-04-13 2001-08-14 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
GB9208135D0 (en) 1992-04-13 1992-05-27 Ludwig Inst Cancer Res Polypeptides having kinase activity,their preparation and use
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
ES2527754T3 (es) 2000-04-25 2015-01-29 Icos Corporation Inhibidores de la isoforma delta de la fosfatidilinositol 3-quinasa humana
EP2088147A1 (en) 2003-12-22 2009-08-12 Arcadia Pharmaceuticals Inc. Dibenzo-condensed azepine, diazepine, oxazepine and thiazepine derivatives as muscarinic agonists and methods of treatment of neuropsychiatric disorders
PT3153514T (pt) 2004-05-13 2021-06-25 Icos Corp Quinazolinonas como inibidoras da fosfatidilinositol 3-quinase delta humana
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
WO2006117670A1 (en) 2005-05-04 2006-11-09 Pfizer Limited 2-amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for the treatment of cancer and viral infections, such as hepatitis c
RS51782B (en) 2005-10-07 2011-12-31 Exelixis Inc. AZETIDINS AS MAK INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
ES2347187T3 (es) 2006-04-26 2010-10-26 F. Hoffmann-La Roche Ag Derivado de tieno(3,2-d)pirimidina, util como un inhibidor de pi3k.
GB0610866D0 (en) 2006-06-02 2006-07-12 Hammersmith Imanet Ltd Novel in vivo imaging compounds
PT2526933E (pt) 2006-09-22 2015-06-23 Pharmacyclics Inc Inibidores da tirosina-quinase de bruton
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
BRPI0717923A2 (pt) * 2006-12-07 2013-10-22 Genentech In '' composto, composição farmacêutica, método para tratar um câncer, processo para a produção de uma composição farmacêutica, usos, métodos para inibir ou modular a atividade da lipídeo quinase e kit ' '
CN101918380B (zh) * 2007-11-21 2014-09-24 解码遗传Ehf公司 用于治疗炎性、心血管和cns病症的取代苯并唑pde4抑制剂
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
CA2772691C (en) * 2009-09-28 2017-10-03 F. Hoffmann-La Roche Ag Benzoxazepin pi3k inhibitor compounds and methods of use
CN104987345A (zh) 2009-09-28 2015-10-21 霍夫曼-拉罗奇有限公司 苯并氧杂*pi3k抑制剂化合物和使用方法
US20120231015A1 (en) * 2009-11-06 2012-09-13 Emory University Fragile x mental retardation protein (fmrp), compositions, and methods related thereto
KR20140032383A (ko) 2011-03-21 2014-03-14 에프. 호프만-라 로슈 아게 Pi3k p110 델타에 대하여 선택적인 벤즈옥사제핀 화합물 및 이의 사용 방법
NO3175985T3 (es) 2011-07-01 2018-04-28
JP5832647B2 (ja) 2011-07-01 2015-12-16 ノバルティス アーゲー がんの治療における使用のためのｃｄｋ４／６阻害剤およびｐｉ３ｋ阻害剤を含む併用療法
UY34632A (es) * 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
MD20140100A2 (ro) 2012-03-05 2015-01-31 Gilead Calistoga Llc Forme polimorfe ale (S)-2-(1-(9H-purin-6-ilamino)propil)-5-fluoro-3-fenilchinazolin-4(3H)-onei
WO2013149184A1 (en) * 2012-03-30 2013-10-03 Brigham Young University Effort modulation for process control of friction stir operations
KR101689946B1 (ko) 2012-06-08 2016-12-26 에프. 호프만-라 로슈 아게 암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물
US9303043B2 (en) 2013-03-13 2016-04-05 Greentech, Inc. Process for making benzoxazepin compounds
JP6260967B2 (ja) * 2013-11-06 2018-01-17 国立大学法人京都大学 放射性ヨウ素標識化合物、及び、これを含む放射性医薬
WO2017001658A1 (en) 2015-07-02 2017-01-05 F. Hoffmann-La Roche Ag Benzoxazepin oxazolidinone compounds and methods of use
UA121678C2 (uk) 2015-07-02 2020-07-10 Ф. Хоффманн-Ля Рош Аг Сполука бензоксазепіноксазолідинонів та способи застосування
EP3851441B1 (en) 2016-12-15 2023-06-28 F. Hoffmann-La Roche AG Process for the preparation of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino) propanamide
WO2018197653A1 (en) * 2017-04-28 2018-11-01 F. Hoffmann-La Roche Ag Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production
WO2020023297A1 (en) 2018-07-23 2020-01-30 Genentech, Inc. Methods of treating cancer with pi3k inhibitor, gdc-0077
TW202027736A (zh) 2018-10-08 2020-08-01 瑞士商赫孚孟拉羅股份公司 用PI3Kα抑制劑及二甲雙胍治療癌症之方法
IL293347A (en) 2019-12-03 2022-07-01 Genentech Inc Combined therapies for the treatment of breast cancer

Also Published As

Publication number Publication date
TWI698440B (zh) 2020-07-11
US20190263793A1 (en) 2019-08-29
PL3567045T3 (pl) 2022-04-19
US20170015678A1 (en) 2017-01-19
CN112062778B (zh) 2024-04-19
KR102014326B1 (ko) 2019-08-26
PH12017502425A1 (en) 2018-07-02
SI3317284T1 (sl) 2020-02-28
RS59740B1 (sr) 2020-02-28
RU2018103454A (ru) 2019-08-05
MA54252A (fr) 2022-04-27
EP3567045B1 (en) 2022-01-12
ES2908300T3 (es) 2022-04-28
IL272277A (en) 2020-02-27
CN107873032B (zh) 2020-07-17
KR102306071B1 (ko) 2021-10-01
KR20180006460A (ko) 2018-01-17
AU2016287463A1 (en) 2017-10-26
PL3317284T3 (pl) 2020-04-30
CN107873032A (zh) 2018-04-03
JP7266630B2 (ja) 2023-04-28
EP3778607A1 (en) 2021-02-17
JP2019178135A (ja) 2019-10-17
US9650393B2 (en) 2017-05-16
EP3567045A1 (en) 2019-11-13
CR20170563A (es) 2018-02-20
PE20181021A1 (es) 2018-06-27
RU2730529C2 (ru) 2020-08-24
JP6880101B2 (ja) 2021-06-02
JP2021119144A (ja) 2021-08-12
KR20190100432A (ko) 2019-08-28
US20240199594A1 (en) 2024-06-20
NZ736222A (en) 2024-05-31
JP2018519307A (ja) 2018-07-19
CA2982708C (en) 2023-10-03
US10851091B2 (en) 2020-12-01
MA42295B1 (fr) 2020-02-28
US20210246129A1 (en) 2021-08-12
PH12020551315A1 (en) 2021-07-05
TWI601732B (zh) 2017-10-11
MX2017016344A (es) 2018-05-02
JP2023103242A (ja) 2023-07-26
BR112017023121A2 (pt) 2018-07-10
CO2017011038A2 (es) 2018-02-09
EP3778607C0 (en) 2023-08-30
SG10201913980SA (en) 2020-03-30
WO2017001645A1 (en) 2017-01-05
HK1253003A1 (zh) 2019-06-06
MA49861A (fr) 2021-05-05
HUE046756T2 (hu) 2020-03-30
CA2982708A1 (en) 2017-01-05
EP3317284A1 (en) 2018-05-09
EP3317284B1 (en) 2019-10-30
IL255200A0 (en) 2017-12-31
US20180127404A1 (en) 2018-05-10
UA121678C2 (uk) 2020-07-10
PT3317284T (pt) 2020-01-10
RU2018103454A3 (es) 2019-11-21
TW201712020A (zh) 2017-04-01
TW201936612A (zh) 2019-09-16
LT3317284T (lt) 2020-01-27
IL272277B (en) 2021-01-31
TW201815798A (zh) 2018-05-01
AU2020204418B2 (en) 2022-02-03
MY195002A (en) 2022-12-30
IL255200B (en) 2020-05-31
EP4212536A1 (en) 2023-07-19
HRP20192349T1 (hr) 2020-03-20
CN112047960B (zh) 2024-08-02
EP3778607B1 (en) 2023-08-30
ES2764497T3 (es) 2020-06-03
TWI649326B (zh) 2019-02-01
US20170210733A1 (en) 2017-07-27
CN112047960A (zh) 2020-12-08
CN111909173A (zh) 2020-11-10
CN112062778A (zh) 2020-12-11
NZ775526A (en) 2024-05-31
ZA201808370B (en) 2023-03-29
TW202108592A (zh) 2021-03-01
AR105238A1 (es) 2017-09-20
US10112932B2 (en) 2018-10-30
DK3317284T3 (da) 2020-01-13
AU2016287463B2 (en) 2020-07-02
MX2020003415A (es) 2021-12-07
PE20211775A1 (es) 2021-09-08
US11760753B2 (en) 2023-09-19
JP6523490B2 (ja) 2019-06-05
AU2020204418A1 (en) 2020-07-23
IL277774A (en) 2020-11-30

Similar Documents

Publication Publication Date Title
CL2017003436A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CO2020000145A2 (es) Carboxamidas como moduladores de los canales de sodio
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
UY37098A (es) Moduladores de ror-gamma
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2015000942A1 (es) Compuestos de benceno sustituido.
BR112018006259A2 (pt) &#34;adjunto compressível com estruturas de suporte intermediárias&#34;
CL2019002810A1 (es) Compuestos inhibidores de ask1 y usos de los mismos.
EA201591403A1 (ru) Спиролактамные модуляторы рецептора nmda и их применение
CR20160203A (es) Inhibidores de tirosina cinasa de bruton
CR20170116A (es) Compuestos que inhiben la proteina mcl-1
CL2019001993A1 (es) Inhibidores selectivos de jak1.
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
CR20140365A (es) Compuestos de carbamato y preparación y uso de los mismos
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
CL2013003160A1 (es) Compuestos derivados de 4h-cromen-4-ona moduladores de la proteina cinasa pi3k; compuestos intermediarios; composicion farmaceutica que los comprende; y utiles en el tratamiento del cancer, agentes antinflamatorios, inmunosupresores, esteroides, analgesicos, leucemia, entre otros.
BR112015011760A2 (pt) composto, uso do composto, e uso de uma composição farmacêutica
ECSP20018487A (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
EA201591404A1 (ru) Спиролактамные модуляторы рецептора nmda и их применение
DOP2016000226A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
ECSP17074645A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa
CR20160047A (es) Inhibidores de rorc2 y sus métodos de uso